Please login to the form below

Not currently logged in
Email:
Password:

Retrophin

This page shows the latest Retrophin news and features for those working in and with pharma, biotech and healthcare.

Retrophin rockets away as rare disease trial hits targets

Retrophin rockets away as rare disease trial hits targets

Retrophin rockets away as rare disease trial hits targets. Sparsentan has potential to become a blockbuster FSG drug, according to analysts. ... What a difference a year makes. Under pressure in 2015, US firm Retrophin now has a positive trial in hand

Latest news

More from news
Approximately 4 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    More recently Retrophin sold its PRV to Sanofi for $245m, so it looks as though values are definitely on the rise!

  • Pharma deals in May 2015 Pharma deals in May 2015

    Sanofi purchased the paediatric PRV from Retrophin for the total consideration of $245m ($150m on closure with two subsequent payments in 2016 and 2017 of $47.7m). ... 300. Retrophin/ Sanofi. Acquisition of priority review voucher [PRV]. For Cholbam

  • Pharma deals during February 2014 Pharma deals during February 2014

    Recently public, Retrophin has acquired Manchester Pharmaceuticals, a speciality pharmaceutical company that focuses on treatments for rare diseases. ... Retrophin is paying a total of $62.5m, including an upfront of $29.5m, plus royalties based on

  • Deal Watch table for February 2014 Deal Watch table for February 2014

    Licence termination. DiaPep277 for type 1 diabetes patients. 72. Manchester Pharmaceuticals / Retrophin.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Amryt Pharma appoints new regulatory affairs head Amryt Pharma appoints new regulatory affairs head

    Amryt Pharma appoints new regulatory affairs head. Derval O’Carroll joins the rare disease-focused biopharma from Retrophin. ... Prior to joining Amryt, she served as senior director of regulatory affairs for rare disease group Retrophin.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics